Diagnostic validity for combined FDG and PIB-PET in Alzheimer*s disease (AD) and differential diagnosis; a regional and multivariate analysis

Diagnostic validity for combined FDG and PIB-PET in Alzheimer*s disease (AD) and differential diagnosis; a regional and multivariate analysis - 'Dual PET' in dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41948

Enrollment

100

Registered

2015-03-23

Start date

2015-07-21

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegeneratieve aandoening/ dementie Alzheimers' disease

Interventions

All subjects will undergo two PET scans on the same day with a PET protocol with [11C] PIB and subsequently [18F] FDG PET. Total duration will be 100 minutes.

Amyloid

Biomarkers

Dementia

PET scan

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age from 50 - 80 yr Willingness to cooperate and sign written informed consent

Exclusion criteria

Exclusion criteria: - History of major psychiatric illness - Medications which may affect outcome - Cerebrovascular disease with cortical infarcts or a Fazekas- score of 2 or higher - Pregnancy - Mentally incompetent to understand full consequence of a written informed consent

Design outcomes

Primary

Measure	Time frame
The results of the PET imaging data and the clinical diagnosis are used in a multimodal, multitracer and multivariate analysis approach to demonstrate regional and voxelwise correlations between FDG PET and PIB PET. SSM/PCA will be applied using software written in-house, based on method of Eidelberg research group (14) with a univariate and multivariate analyis method. Outcome is measured in so-called z-scores.	—

Measure

Time frame

The results of the PET imaging data and the clinical diagnosis are used in a multimodal, multitracer and multivariate analysis approach to demonstrate regional and voxelwise correlations between FDG PET and PIB PET. SSM/PCA will be applied using software written in-house, based on method of Eidelberg research group (14) with a univariate and multivariate analyis method. Outcome is measured in so-called z-scores.

—

Secondary

Measure	Time frame
The correct differentiation of AD between normal healthy controls (CP) and frontotemporal dementia (FTD) and Lewy Body dementia (DLB).	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)